From Name:
From Email:
To Name:
To Email:

Optional Message:


Experimental Heart Failure Medication Meets Primary Endpoint in Phase 2B Trial

from Cardiovascular Business

Vericel Corp. announced March 10 that its experimental drug to treat advanced heart failure due to ischemic dilated cardiomyopathy met the primary endpoint in a phase 2b clinical trial. After a year of treatment, patients with end-stage heart failure due to ischemic dilated cardiomyopathy acute decompensated heart failure who received ixmyelocel-T had reductions in the total number of deaths, cardiovascular hospitalizations or unplanned outpatient and emergency department visits compared with those who received placebo. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063